Cibus Extends Cash Runway to Q1 2027 with $37M Equity Raise, Beats Q1 Revenue Estimates
CBUS sits 29% above its 52-week low of $1.09 on light trading volume (0.4× avg).
Summary
Cibus, Inc. reported Q1 revenue of $1.68 million, surpassing analyst estimates of $1.62 million, and narrowed its net loss from the prior year. Critically, the company raised $37 million in equity during the quarter, a significant financing event relative to its market capitalization. This capital infusion is expected to extend Cibus's cash runway into late Q1 2027, a material improvement from the late Q3 2026 projection in its recent 10-K which included a going concern warning. The improved liquidity position addresses a key financial risk, allowing the company to continue advancing its Rice herbicide tolerance and Sustainable Ingredients programs. Investors will now monitor the company's progress on commercialization milestones and continued cash burn management.
At the time of this announcement, CBUS was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107.6M. The 52-week trading range was $1.09 to $4.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.